PAREXEL Named Company of the Year for the Pharmaceuticals Industry with a Gold Stevie from the American Business Awards
02 June 2016 - 11:00PM
Business Wire
Company also awarded Gold Stevie Award for Best
Public Relations Event
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services provider, has been named Company
of the Year – Pharmaceuticals in the 14th Annual American Business
AwardsSM. The judges awarded PAREXEL a Gold Stevie® Award and
recognized the Company’s investments in innovation and expanded
capabilities across the drug development continuum in 2015 as
specifics for the accolade.
“All of us at PAREXEL are committed to advancing the success of
the biopharmaceutical industry in our mission to prevent and cure
disease. We are honored to be recognized by The American Business
Awards for our accomplishments in this regard,” said Josef von
Rickenbach, Chairman and Chief Executive Officer, PAREXEL
International. “This award is a tribute to the expertise of our
more than 18,000 employees around the globe. They are the ones who
provide innovative solutions and high-quality work to our clients
every day, ensuring PAREXEL’s success.”
The American Business Awards recognized the Company for
launching several new services, processes, product innovations, and
academic programs in 2015. PAREXEL enhanced several critical
aspects of drug development with a focus on reducing clinical trial
start-up times, streamlining navigation of the global regulatory
environment, enhancing regulatory submission and product
registration management tools, and training the next generation
biopharmaceutical workforce.
In addition to the Company of the Year – Pharmaceuticals
award, PAREXEL also earned a Gold Stevie Award for Best Public
Relations Event. The American Business Awards recognized the
Company for increasing awareness of PAREXEL as a multinational
employer of choice with significant job opportunities in
Dublin.
The American Business Awards are the nation’s premier business
awards program. Winners and honorees of The American Business
Awards were selected from more than 3,400 entries. More than 250
professionals worldwide participated in the judging process to
select this year’s Stevie Award winners.
“The judges were extremely impressed with the quality of entries
we received this year. The competition was intense and every
organization that has won should be proud,” said Michael Gallagher,
president and founder of the Stevie Awards.
About the Stevie AwardsStevie Awards are conferred in
seven programs: the Asia-Pacific Stevie Awards, the German Stevie
Awards, The American Business Awards, The International Business
Awards, the Stevie Awards for Women in Business, the Stevie Awards
for Great Employers, and the Stevie Awards for Sales & Customer
Service. Stevie Awards competitions receive more than 10,000
entries each year from organizations in more than 60 nations.
Honoring organizations of all types and sizes and the people behind
them, the Stevies recognize outstanding performances in the
workplace worldwide. Learn more about the Stevie Awards at
http://www.StevieAwards.com.
About PAREXEL InternationalPAREXEL International
Corporation is a leading global biopharmaceutical services company,
providing a broad range of expertise-based clinical research,
consulting, medical communications, and technology solutions and
services to the worldwide pharmaceutical, biotechnology and medical
device industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, and
reimbursement. PAREXEL Informatics provides advanced technology
solutions, including medical imaging, to facilitate the clinical
development process. Headquartered near Boston, Massachusetts,
PAREXEL has offices in 82 locations in 51 countries around the
world, and had approximately 18,450 employees in the third quarter.
For more information about PAREXEL International, visit
www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its affiliates.
All other trademarks are property of their respective owners.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160602005104/en/
PAREXEL International CorporationCristi Barnett, +1
781-434-4019Cristi.Barnett@PAREXEL.comorPAN CommunicationsMatthew
Briggs, +1 617-502-4300PAREXEL@pancomm.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Apr 2024 to May 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From May 2023 to May 2024